Synonyms: PRO 140 | PRO-140 | PRO140 | Vyrologix®
Compound class:
Antibody
Comment: Leronlimab (PRO140) is a humanized anti-CCR5 (C-C motif chemokine receptor 5) monoclonal antibody [5-6]. It was originally developed by CytoDyn as a novel strategy to manage CCR5-tropic HIV infection [4].
SARS-CoV-2 and COVID-19: Leronlimab has been administered to a number of patients with severe COVID-19, to determine its potential to reduce cytokine storm caused by this disease. |
References |
1. Burger DR, Parker Y, Guinta K, Lindner D. (2018)
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant, 24 (2): 260-266. [PMID:29128556] |
2. CytoDyn.
Press Release April 09, 2020 (Southern California MC). Accessed on 27/04/2020. Modified on 27/04/2020. CytoDyn, https://www.cytodyn.com/newsroom/press-releases/detail/412/severely-ill-covid-19-patient-at-leading-southern |
3. CytoDyn.
Press release April 09, 2020. Accessed on 27/04/2020. Modified on 27/04/2020. CytoDyn, https://www.cytodyn.com/newsroom/press-releases/detail/413/blood-samples-at-day-0-3-and-7-for-severely-ill-covid-19 |
4. Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ. (2018)
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. HIV Clin Trials, 19 (3): 85-93. [PMID:29676212] |
5. Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. (2019)
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology. Cancer Res, 79 (19): 4801-4807. [PMID:31292161] |
6. Miao M, De Clercq E, Li G. (2020)
Clinical significance of chemokine receptor antagonists. Expert Opin Drug Metab Toxicol, 16 (1): 11-30. [PMID:31903790] |
7. Olson WC, Maddon PJ, Tsurushita N, Hinton PR, Vasquez M. (2006)
Anti-CCR5 antibody. Patent number: US7122185B2. Assignee: CytoDyn Inc; AbbVie Biotherapeutics Inc. Priority date: 22/02/2002. Publication date: 17/10/2006. |